



## Narrative review

## How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories?

E. Nagy <sup>1,\*</sup>, L. Boyanova <sup>2</sup>, U.S. Justesen <sup>3</sup>, on behalf of ESCMID Study Group of Anaerobic Infections

<sup>1)</sup> Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary

<sup>2)</sup> Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria

<sup>3)</sup> Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark

## ARTICLE INFO

## Article history:

Received 14 December 2017

Received in revised form

9 February 2018

Accepted 11 February 2018

Available online xxx

Editor: L. Leibovici

## Keywords:

Anaerobic bacteria

Antimicrobial susceptibility determination

Identification

Isolation

## ABSTRACT

**Background:** There has been increased interest in the study of anaerobic bacteria that cause human infection during the past decade. Many new genera and species have been described using 16S rRNA gene sequencing of clinical isolates obtained from different infection sites with commercially available special culture media to support the growth of anaerobes. Several systems, such as anaerobic pouches, boxes, jars and chambers provide suitable anaerobic culture conditions to isolate even strict anaerobic bacteria successfully from clinical specimens. Beside the classical, time-consuming identification methods and automated biochemical tests, the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry has revolutionized identification of even unusual and slow-growing anaerobes directly from culture plates, providing the possibility of providing timely information about anaerobic infections.

**Aims:** The aim of this review article is to present methods for routine laboratories, which carry out anaerobic diagnostics on different levels.

**Sources:** Relevant data from the literature mostly published during the last 7 years are encompassed and discussed.

**Content:** The review involves topics on the anaerobes that are members of the commensal microbiota and their role causing infection, the key requirements for collection and transport of specimens, processing of specimens in the laboratory, incubation techniques, identification and antimicrobial susceptibility testing of anaerobic bacteria. Advantages, drawbacks and specific benefits of the methods are highlighted.

**Implications:** The present review aims to update and improve anaerobic microbiology in laboratories with optimal conditions as well as encourage its routine implementation in laboratories with restricted resources. **E. Nagy, Clin Microbiol Infect 2018;■:1**

© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

## Introduction

Human pathogenic anaerobic bacteria were first discovered and identified in the middle of the nineteenth century. However, it was difficult at that time to obtain pure cultures for many of these organisms [1]. Even later, anaerobic infections were the most commonly overlooked of all bacterial infections, especially when

the anaerobic bacteria were present in mixed culture and one or more aerobic or facultative anaerobic pathogens were grown on the same media at the same time. Use of insufficient anaerobic incubation techniques will often permit only isolation of the most common anaerobic pathogens, the members of the *Bacteroides fragilis* group or *Clostridium perfringens*, which are known as 'moderate' anaerobes surviving oxygen levels up to 2%–8%. This may let the microbiologist think that his/her techniques for anaerobic culture are fully adequate, as they can regularly isolate 'anaerobes'. It is difficult to provide a correct and practical definition of the term 'anaerobe'. Anaerobic bacteria may differ

\* Corresponding author. E Nagy, Institute of Clinical Microbiology, University of Szeged, 6701 Szeged, P.O. Box 427, Hungary.

E-mail address: [nagy.erzsebet@med.u-szeged.hu](mailto:nagy.erzsebet@med.u-szeged.hu) (E. Nagy).

significantly in their tolerance to atmospheric oxygen and in how low oxygen levels are needed for them to multiply. A practical definition was formulated by Professor Finegold in 1977: 'anaerobe is a bacterium that requires a reduced oxygen tension for growth and fails to grow (form colonies) on the surface of solid media in 10% CO<sub>2</sub>, in air (18% oxygen)' [1].


Various kinds of equipment to provide a suitable anaerobic environment and different commercially available media for culturing the wide range of anaerobic bacteria with different requirements have been introduced into routine laboratories. The application of 16S rRNA gene-sequencing-based identification for difficult to identify anaerobes, and the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the direct identification of them from the primary culture plate or from the anaerobic subculture plate, have made it possible to provide accurate and timely information about their role in infections. New anaerobic species have been detected and identified through studies on the composition of the normal gut microbiota, using a new culture tool called 'culturomics' [2,3]. All of these achievements have increased the interest for anaerobes in clinical situations and beyond. It has become increasingly important in human medicine to identify anaerobic infections. One reason is that there is a growing evidence of infections caused by more virulent anaerobic species such as *Clostridioides* (*Clostridium*) *difficile* PCR ribotype 027, which produces ≥16-fold more toxin than classical strains [4], or *Fusobacterium necrophorum* causing some cases of 'culture-negative' chronic tonsillitis [5], or enterotoxigenic *B. fragilis* in sepsis and colon carcinoma [6,7]. Another reason is the constant increase of immunocompromised patients such as patients with diabetic foot ulcers, which often involve neglected anaerobes [8,9]. Last, there are dynamic changes in antibiotic

resistance of anaerobes. Since 2000, increasing resistance rates in *Bacteroides/Parabacteroides* spp. to β-lactam/β-lactamase inhibitor combinations, clindamycin and carbapenems, in *Prevotella* spp. to β-lactams, in Gram-positive anaerobic cocci to clindamycin, and in *C. difficile* and *Bacteroides/Parabacteroides* spp. to metronidazole have been reported in Europe [10–12]. A special concern is metallo-β-lactamase production in *B. fragilis* (Division II isolates) conferred by the *cfa* gene, which may lead to carbapenem resistance. In some studies, the *cfa* gene has been detected in nearly 40% of the *B. fragilis* isolates [13]. Multidrug resistance has also been detected among *B. fragilis* clinical isolates in different countries [14–16].

Surveillance studies about anaerobe culture techniques, identification and susceptibility testing methods carried out in routine laboratories in the USA and Belgium have shown that there are great differences in the methods used in different laboratories, where diagnostics other than detecting the presence of toxigenic *C. difficile* in faeces is carried out in-house [17,18]. The aims of this review are to discuss the presence of anaerobes in commensal microbiota and in infectious processes, and to present optimal methodology for carrying out anaerobic diagnostics of human infections.

#### Anaerobes as members of commensal microbiota and risks of anaerobic infections

Anaerobes are abundant in commensal microbiota throughout different body sites being the dominating or less dominating part of the microbiota (Fig. 1) [3,19–21]. Low oxygen concentration in the intestinal and urogenital tract favours the abundance of anaerobic bacteria in these sites. In more aerated sites such as the oral cavity and skin, the anaerobes inhabit protected sites where cohabiting aerobic/facultative bacteria consume the oxygen [20]. This is



**Fig. 1.** Most common anaerobic species/groups of the commensal microbiome at different body sites. GPAC, Gram-positive anaerobic cocci.

essential as most anaerobic infections are endogenous and favoured by damaged mucosal/cutaneous barriers, which allow their penetration into normally sterile tissues often together with aerobic/facultative bacteria. Importantly, from most infections where anaerobes are present together with aerobic/facultative bacteria, it is difficult to isolate them in pure culture for identification. A great variety of species belonging to strict anaerobic genera have been proven to cause infections in almost all regions of the body and may lead to serious bloodstream infections as well (Table 1) [21,22]. Besides the well-known species, the spectrum of the anaerobic bacteria isolated from infections in humans is increasing, due to better isolation and identification possibilities. New anaerobic genera and species have been shown to be present in serious infections, such as the spore-forming, Gram-positive rod, *Robinsoniella peoriensis*, the non-spore-forming Gram-positive rods *Solobacterium moorei* and *Turicibacter sanguinis*, *Ruminococcus gnavus* or *Oscillibacter ruminantium*, causing bacteraemia and other infections, just to mention a few examples [23–25].

Anaerobic microbiology is not routinely performed in many laboratories because of technical and financial reasons. However, the first steps for cost reduction depend on the clinicians' knowledge of the characteristics of anaerobic infections and on laboratory policy to reject unacceptable specimens such as those from body sites containing anaerobic commensal microbiota (Table 2) [18,19,21,26–28].

### Key requirements for collection and transport of specimens for anaerobic microbiology

To fully benefit from the anaerobic microbiology, clinicians should collect and send clinical specimens to the laboratory

according to the specific recommendations (Table 2) [19,21,26,27,29]. The specimens for anaerobe culture should be:

- collected at an appropriate time—before the start of antibiotic therapy, or if this is not possible, just before the following drug administration;
- collected at the infection site—e.g. for wound infections and open abscesses, deep aspirates/tissue biopsies at the advancing wound edge (where the bacteria multiply) rather than pus or superficial specimens, and for closed abscesses, deep needle aspirates of the lesion and close to the borders;
- aspirates and tissue biopsies instead of swabs—cotton wool swabs are porous, prone to desiccation and contain inhibitory fatty acids—it is best to use swabs made of synthetic fibres;
- free from contamination with commensal microbiota—therefore, debridement and skin decontamination are needed; sufficient volumes should be taken (e.g. 8–10 mL of blood/bottle, >1–2 mL aspirates, ≥1 g tissues, ≥5 mL of watery/semi-formed stool specimens for *C. difficile*);
- inserted in anaerobic transport media (ATMs)—the best ATMs are commercially available oxygen-free transport tubes/vials with pre-reduced and anaerobically sterilized (PRAS) anaerobic media, if not available, Stuart's, Cary–Blair or Amies transport media can be prepared in the laboratory. Specimens should be deeply inserted into the ATMs or onto the agar surface (after ethanol cleaning of the ATM stopper) if PRAS ATMs are used and the specimens are liquid;
- stored and transported at room temperature and not in a refrigerator—at low temperatures, oxygen diffusion is increased;
- sent to the laboratory within 2 h in ATMs—although, if delay is unavoidable, they can be accepted even after 8–48 h. If no ATMs

**Table 1**  
Common detection rates of anaerobes in some clinically important infections [1,19–21,26,28]

Prevalence of anaerobes <sup>a</sup>	Very high (≥70%–100%)	High (40%–70%)	Moderate (13%–45%)	Low (4%–10%)	Very low (≤1%)
Head and neck	Most dental and oral infections, involving head and neck cellulitis and abscesses, root canal infections, peritonsillar abscess, chronic sinusitis, post-surgical infections	Chronic otitis media, mastoiditis	Ocular infections (dacryocystitis, post-traumatic endophthalmitis, perforated corneal ulcers), cervical lymphadenitis, serous otitis media, tonsillopharyngitis	Acute sinusitis, acute otitis media	
Blood	Intra-abdominal sepsis, septic abortion	Bacteraemia after oral surgery/tooth extraction		Bacteraemia due to endocarditis	
CNS	Brain abscess, subdural empyema			CNS shunt infections	Meningitis
Pulmonary	Lung abscess, aspiration pneumonia, necrotizing pneumonia, pleural empyema		Bronchiectasis, nosocomial pneumonia,		
Skin/soft tissue	Gas gangrene, breast abscess, synergistic necrotizing cellulitis, perianal and perirectal abscess, infected diabetic gangrene, pilonidal abscess, infections after trauma, acne vulgaris	Wound infections, abscesses, cellulitis, necrotizing fasciitis, bite wound, diabetic foot infection, infected decubitus ulcers	Impetigo		
Abdominal	Most intra-abdominal infections, appendicular abscess, appendicitis with peritonitis, post-surgical abdominal infections	Liver abscess	Biliary tract infections, ascites and hepatic abscess		
AAD	Pseudomembranous colitis ( <i>Clostridium difficile</i> )		Overall AAD ( <i>Clostridium difficile</i> and <i>Clostridium perfringens</i> )		
Bone/joint		Orthopaedic device infections	Osteomyelitis, infections without orthopedic devices	PJIs	
Urogenital	Most female genital tract infections (pelvic inflammatory disease, pelvic abscesses, endometritis, vaginal cuff abscess, bacterial vaginosis)				Urinary tract infections

Abbreviations: AAD, antibiotic-associated diarrhoea; CNS, central nervous system; PJIs, prosthetic joint infections.

<sup>a</sup> Detection rates vary according to the methods used.

**Table 2**

Acceptable and unacceptable specimens for anaerobic microbiology [18,19,21,26,27,29,33]

Infection site	Acceptable specimens	Unacceptable specimens
Blood	Blood (8–10 mL/bottle or acc. to the weight) in anaerobic blood bottles	Catheter/catheter-tip samples
Central nervous system	Tissue biopsies or needle aspirates through intact decontaminated surface	Surface swabs
Head and neck	Percutaneous needle aspirates, surgical specimens. For Lemierre syndrome aspirates, tissue biopsies. For actinomycosis sulphur granules as well	Oral, nose and throat swabs except for Lemierre syndrome
Periodontal	Abscess aspirates, subgingival pocket samples (by periodontal curettes or sterile paper points in the canal)	Surface gingival and oral swabs
Ear	In otitis media: aspirates by tympanocentesis (with sterile micropipettes)	Surface material
Eye	Corneal scraping, vitreous fluid needle aspirates, conjunctival swabs	As above
Abscesses	Closed abscess: needle aspirates through intact decontaminated tissue, surgical samples; fistulas/sinuses: deep plastic catheter aspirates after disinfected skin opening; open abscesses: see Wounds	Skin/mucosal surface swabs, pus
Pulmonary	Pleural fluid, lung and transtracheal aspirates, lung-tissue biopsies, deep bronchial secretions taken with double-lumen (protected) catheter	Nasopharyngeal swabs, sputum
Abdominal cavity	Peritoneal and ascites fluid aspirates, surgical biopsies, bile aspirates	Ileostomy/colostomy samples
Stool	Only for <i>Clostridium difficile</i> or <i>Clostridium botulinum</i>	For other anaerobes
Female genital tract	Tissue biopsies, pelvic infection aspirates (by culdoscintesis) peritoneal fluid, endometrial specimens (by protected catheters), surgical specimens	Cervical/vaginal swabs (except for bacterial vaginosis)
Bone	Aspirate, bone biopsies. Taking several biopsies is recommended	Swabs, soft-tissue samples
Joint, prosthetic joint	Synovial fluid aspirates in anaerobic blood culture bottles, periprosthetic biopsies in anaerobic broth media	Surface swabs of wounds/fistulas
Wounds/soft tissues	Deep biopsy sampling, deep wound aspirates at the advancing wound edge after debridement and cleaning the surface with sterile saline or alcohol	Surface swabs, pus, sinus tracts
Decubitus or skin ulcers	Needle aspirates or tissue biopsies. Deep sampling from the base of lesion	Surface material, swabs
Diabetic foot ulcers	Bone biopsies (surgical or after debridement and surface disinfection)	Tissue samples less suitable
Urine	Bladder urine (suprapubic bladder aspirates)	Voided and catheterized urine

are available, large volume ( $\geq 2$  mL) aspirates should be placed into sterile containers and in such cases, prompt transport (within  $\leq 1$  h) is needed.

### Processing specimens in the laboratory for culturing anaerobes

All clinical microbiology laboratories that accept specimens for anaerobic culture have to have facilities to isolate anaerobes and screen for the major anaerobic groups (Level 1 and 2 anaerobic laboratories) [21]. For definitive identification and antimicrobial susceptibility testing (AST), isolated anaerobes should be referred to reference laboratories. Level 3 anaerobic laboratories should identify anaerobes to genus and species level using phenotypic and enzymatic tests and should determine some presumptive antibiotic sensitivity. Level 4 anaerobic laboratories should provide final identification using MALDI-TOF MS and, if needed, 16S rRNA gene sequencing and should perform quantitative AST [19,21].

After visual examination of the acceptable specimens (Table 2) all samples should be homogenized in liquid medium (e.g. thioglycolate broth). Direct Gram-staining of the specimen is mandatory for anaerobic diagnostics [30]. It can reveal the presumptive involvement of some anaerobic species with characteristic morphology, such as *Fusobacterium nucleatum*, *B. fragilis* or *C. perfringens* [19]. In the case of urinary tract infections, which persist with negative aerobic culture growth, the rare uropathogen *Actinotignum (Actinobaculum) schaali* can be detected by Gram-staining, indicating the need for prolonged incubation in  $\text{CO}_2$  or inoculation on anaerobic media [31]. The direct Gram-staining also makes it easy to distinguish between wound contamination (showing abundance of squamous epithelial cells) and infection (exhibiting both bacteria and inflammatory cells) [26]. Moreover, the technique has shown higher sensitivity compared with culture in the case of actinomycosis, where branching filamentous Gram-positive rods may be observed in specimens from abscesses or sinus tracts [32].

The initial anaerobic culture process should include careful plating on selective and non-selective blood agar plates (freshly prepared in house or commercially available), as well as in liquid anaerobic media (thioglycolate broth). The primary enriched (with horse or sheep blood, vitamin K1 and haemin) non-selective media should allow the growth of all clinically significant anaerobes. Many laboratories in the USA prefer to use commercially available PRAS media to isolate fastidious anaerobic pathogens [21]; however, homemade fresh anaerobic media can also be successfully used. Based on the Gram-staining results of the specimen, further selective media (*Bacteroides* bile esculin agar, kanamycin–vancomycin laked blood agar, phenylethyl alcohol agar, egg yolk agar) can be inoculated [19]. If isolation of *C. difficile* is needed from stool samples, the classical cycloserine–cefoxitin fructose agar or other commercially available selective chromogenic media should be used [21,33]. Few laboratories process specimens in an anaerobic chamber. Usually, work is performed outside an anaerobic environment, but to limit oxygen exposure, it is important to place inoculated media into an anaerobic environment (such as plastic envelopes, boxes, jars, or automated gas flushing instruments, e.g. Anoxomat or anaerobic chambers) within 15–20 min after inoculation. Suggested incubation time is usually 48 h, but some anaerobes (such as *C. perfringens*) may form colonies earlier. Several slow-growing anaerobes, however, may need much longer primary incubation time (up to 3–5 days) to form colonies suitable for subculturing or direct identification by the MALDI-TOF MS. The anaerobic broth should be held for up to 14 days in special cases such as detection of *Cutibacterium* spp. from prostatic joint infections. Control of anaerobiosis during incubation is strongly recommended to be sure that even strict anaerobes will form colonies [19,21,34].

### Anaerobe incubation techniques

In routine laboratories, the classical Hungate role tube method was rapidly replaced by the easier-to-use anaerobic jars, boxes, pouches and chambers for isolation of anaerobic bacteria. Various

systems for anaerobiosis have different advantages and disadvantages [19,21]. The most expensive anaerobic chambers allow inoculation, inspection and subculturing in a permanent anaerobic environment to ensure viability of fastidious, slow-growing anaerobes and to check the plates daily for growth. Anaerobic pouches, boxes and jars need more organized specimen processing as culture media are inoculated in air. Jars and boxes should not be opened before 48 h of incubation to prevent premature death of some slow-growing anaerobes by exposure to air during their logarithmic growth phase. Today, automated gas flushing instruments (Anoxomat) can also be used to shorten the exposure of inoculated plates to air because an anaerobic atmosphere can be achieved within minutes [34,35]. If the clinical situation (symptoms of gas gangrene) or initial Gram-staining result suggests the presence of *C. perfringens*, it may be prudent to incubate plates individually in anaerobic pouches so that the plate may be examined earlier. The reduced condition for any anaerobic system should be monitored by the addition of anaerobe indicator strips (with methylene blue or resazurin), which become colourless in the low concentration of oxygen needed for appropriate growth of most clinically important anaerobes. Cost-effective biological indicators such as a subculture of *Pseudomonas aeruginosa* on Simmon's citrate slant [19] or measuring the inhibition zone diameter of a 5-µg metronidazole disc on an aerotolerant *C. perfringens* control strain [34], can also be used.

To simplify anaerobe bacteriology, a medium containing oxygen-removing enzymes such as oxyrase was recommended [36]. OxyDish™ is a tightly sealed Petri dish with PRAS blood agar medium containing the enzyme (OxyRase™) that removes oxygen from the medium and the space above the agar after inoculation and maintains anaerobic conditions during the incubation without using anaerobic jars or chamber [36]. Another approach to eliminate the use of anaerobic incubation systems is adding antioxidant molecules such as ascorbic acid, glutathione and uric acid to the blood agar plates (series of R medium—‘quasi-universal’ media) to avoid oxygen toxicity during incubation of the plates in ambient air [37]. Both approaches may simplify laboratory procedures; however, a careful evaluation of their performance is needed for isolation of strict anaerobic bacteria from specimens containing a mixed bacterial population in clinical practice.

### Identification of anaerobes

Initial examination of colonies should be performed using a stereomicroscope or at least a strong magnifying glass. Colony morphologies that appear similar when observed at a distance, can be differentiated when magnified, and the presence of tiny colonies near larger ones can be discerned. All different colonies should be isolated and plated on an anaerobic blood agar plate, a chocolate agar plate and a spot on a glass slide for Gram-staining. Care should be taken that the same colony goes onto both plates and the slide.


Classical identification of anaerobes was based on a series of biochemical tests in PRAS test tubes with different sugars and various other substrates incubated for 1–6 days depending on the growth rate of the isolate. Careful evaluation of cell morphology and detection of alcohol and short-chain fatty acids by gas–liquid chromatography later became the basis of the identification of a wide range of anaerobic bacteria [38]. Nowadays some routine laboratories still rely on a presumptive identification carried out after subculturing the colonies from the primary plate in an anaerobic environment [19,21]. Beside investigation of colony and Gram-stain morphology and motility, a combination of rapid biochemical spot tests (such as detection of indole, catalase, nitrite, urease positivity) and susceptibility to special potency antibiotic

discs such as kanamycin (1000 µg), vancomycin (5 µg) and colistin (10 µg) can be used for the identification of major groups of anaerobes with clinical relevance. This presumptive identification is cost-effective, but takes 24–48 h after isolation of the colonies on the primary plate. Growth in the presence of 20% bile and the pigmentation of the colonies (brown to black) of some *Prevotella* and *Porphyromonas* spp. is characteristic after ≥4 days of incubation. Long-wave UV light can be used to detect characteristic fluorescence of some colonies (e.g. *C. difficile*—chartreuse, *Prevotella melaninogenica*, *Porphyromonas asaccharolytica*—brick red) [19,21].

More detailed identification can be carried out by commercially available manual or automated identification kits, using panels to assess the ability of the isolated anaerobes to react with a limited number of carbohydrates and other substrates after 24-h incubation in an anaerobic environment (detection of inducible enzymes). Other systems detect preformed enzymes and the kits should be incubated aerobically for 4–6 h; however, a high inoculum is needed that is difficult to achieve in the case of slow-growing anaerobic bacteria with tiny colonies. These systems are hindered by a limited number of substrates to provide proper differentiation for a wide range of anaerobic species; moreover, many anaerobic bacteria are non-reactive in biochemical tests. Many clinically important or newly described taxa may be lacking from the databases. Users must be aware that databases of these products are rarely updated [39,40].

Recently, MALDI-TOF MS based on soft ionization of large molecules such as proteins, peptides, lipids, sugars and DNA, has been shown to perform very well for the identification of anaerobes [41–43]. Microorganisms are identified by comparing their mass spectrum with those of known reference strains. The initial cost of the instrument may seem prohibitive to many microbiological laboratories, but it is inexpensive to run and will identify anaerobes, as well as most other microorganisms, quickly and accurately. As MALDI-TOF MS is a very sensitive method, only a very small amount of biomass is needed for correct identification. This provides an early identification for anaerobes, very often directly from the primary culture plates, without additional subculturing and testing for aerotolerance. However, very small colonies from mixed culture may need subculturing for a shorter or longer time before MALDI-TOF MS identification. Applying the latest updates of the databases associated with the two widely used MS systems (Bruker Biotype - Bruker Daltonik, Germany, VITEK MS - bioMérieux, France) is the prerequisite for the successful use of this technique. The data libraries for anaerobes must include not only reference strains, but also clinical strains corroborated by molecular sequencing methods [42,44,45]. During the past few years, several studies have proved the superiority of MALDI-TOF MS during routine identification of anaerobes compared with different automated or manual biochemical identification kits [46–49]. Sample preparation, incubation time, but not culture media or, in most cases, exposure to oxygen can influence the quality of the identification of anaerobes by MALDI-TOF MS [50,51]. However, the MS-based name of an isolate has to correlate with the colony and Gram-stain morphology. Further possibilities such as typing of anaerobic bacteria (*B. fragilis*, *C. difficile* or *Cutibacterium acnes*) at the subspecies level, determination of resistance and direct identification of anaerobic blood culture isolates can also help in routine anaerobic diagnostics [42,52,53].

When the above-mentioned methods fail to correctly identify a clinically important anaerobic strain to the genus or species level, sequencing of genetic markers such as a portion of the 16S rRNA gene or other genetic elements may be used for identification [22,54]. Fig. 2 and Table 3 summarize the possibilities of species identification of anaerobic bacteria with pros and cons including the time needed for genus/species determination.



**Fig. 2.** Species identification of anaerobic bacteria by different methods and the minimum time needed.

### Antimicrobial susceptibility testing of anaerobic bacteria

Resistance patterns of many anaerobes have changed significantly over the last decades, both within and between countries. This has made antimicrobial susceptibility of anaerobic bacteria increasingly unpredictable [11,55]. There are specific infections from which anaerobic isolates should be considered for AST including bacteraemia, brain abscesses, endocarditis, osteomyelitis, joint infections, infections of prosthetic devices and vascular grafts. There are also some species of *Clostridium*, *Bacteroides*, *Prevotella*,

*Fusobacterium*, *Bilophila* and *Sutterella*, which are highly virulent and have unpredictable susceptibility patterns. Persistence of severe infection despite a proper antibiotic therapy is also a major indication for the AST of anaerobic bacteria.

A methodology for easy, inexpensive and flexible routine AST of anaerobic bacteria is not readily available, but is very much needed. Some anaerobic bacteria are extremely sensitive to oxygen and the impaired growth will often result in overcalling susceptibility. The activity of metronidazole is also dependent on strict anaerobic conditions and even small amounts of oxygen will greatly reduce

**Table 3**

The available methods for species identification of anaerobic bacteria [19,21,38,40,42,43]

Method	Pros	Cons	Comments
Wide range of biochemical test in slants	Different substrates can be tested in PRAS medium	Time consuming, labour intensive, subjective reading	Classical method for identification anaerobes
Presumptive identification	Easy to perform, flexible, early result is possible	Only limited number of genera, species (~25–30) can be identified	If needed confirmation by more developed method is possible
Manual identification kit with 24–48 h incubation	Easy to perform, small inoculum is enough	Anaerobe environment is needed, no time gained till reporting	Limited database
Automated systems using preformed enzymes kits	Timely result, easy to perform, no anaerobic environment is needed	Special equipment is needed	Limited database
MALDI-TOF MS	Rapid, reproducible, accurate identification, cost effective to identify several isolates, little biomass is needed, direct identification from the primary plate without confirming anaerobiosis, direct identification from positive blood cultures	Initial cost is high, back up equipment is needed in high-throughput laboratories	Further developments in progress to use it for typing and antibiotic susceptibility testing
Sequencing	Gold standard for species identification, description of new species, decreasing cost and time	Special knowledge and equipment are needed	Molecular assessment capability is needed (bioinformatics)

Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PRAS, pre-reduced and anaerobically sterilized.

**Table 4**

The available methods for antimicrobial susceptibility testing of anaerobic bacteria [19,56,58,62]

Method	Pros	Cons	Comment
Agar dilution	Validated method. Cost effective if many isolates are examined at the same time	Labour intensive	Reference standard
Broth microdilution	Commercial assays are available, multiple antibiotics in one microtiter tray, relatively inexpensive	Fixed antibiotics in commercial products, medium labour intensive, only suitable for the <i>Bacteroides fragilis</i> group	Limited number of studies on commercial products
Gradient strips	Easy and flexible, can detect heteroresistance to some antibiotics	Expensive	Concerns about performance and warnings on specific agents
Disc diffusion	Inexpensive, easy, flexible	No validated method, studied mainly fast-growing anaerobic species	EUCAST development project

the conversion of metronidazole to active metabolites, resulting in pseudo-resistance. The available methods for anaerobic AST (Table 4) with pros and cons and for detection of special resistance mechanisms are described below.


Agar dilution is considered as the reference standard for AST of anaerobic bacteria. A comprehensive description of the standard from the CLSI is available, with the most recent update from 2012 [56]. The method is most cost-effective if many isolates are examined at the same time (>100) and is the method for use when carrying out surveillance studies (Fig. 3). For routine purposes, the method is not practical for most laboratories. A modified version is breakpoint testing with an agar containing the breakpoint concentration, i.e. no growth on the agar would categorize an isolate as susceptible. This is a very rough estimate of susceptibility and does not include intermediate susceptibility.

A standard broth dilution method, adapted for anaerobic bacteria with supplemented *Brucella* broth has been described by the CLSI [56]. However, for several years a caveat has been included which states: 'Until further studies are performed to validate this procedure for testing other organisms, it should be used only for testing members of the *B. fragilis* group.' [56]. There are commercial micro-dilution trays with freeze-dried antibiotics available and only the broth has to be added; however, some anaerobes such as Gram-positive anaerobic cocci cannot grow well in broth. Very few studies have evaluated the commercial broth micro-dilution systems for anaerobic bacteria including the *B. fragilis* group [57,58].

Gradient strips from several manufacturers are available for anaerobic AST and are frequently used in routine clinical microbiology laboratories. The standard medium for gradient strip AST recommended by the manufacturer is the supplemented (vitamin K1 and haemin) *Brucella* agar with 5% sheep blood. The most recent and comprehensive evaluation of gradient strips from two different manufacturers in comparison with agar dilution was published by Rennie et al. in 2012 [59]. The study applied US Food and Drug

Administration (FDA) criteria for comparison with the reference standard and included amoxicillin-clavulanate, imipenem, metronidazole and penicillin. Overall none of the strips complied with the FDA requirements for essential agreement (>90%) and the rate of very major errors for metronidazole was >10% for both strips tested (FDA requirement <1.5%). In 2015, EUCAST issued a warning concerning problems with piperacillin-tazobactam gradient strips from two manufacturers [60]. Gradient strips are the most convenient AST method for most routine laboratories at the moment; however, it is imperative that the method is performed strictly according to the manufacturer's instructions and always include the relevant quality control strains, e.g. *B. fragilis* ATCC 25285 and *C. difficile* ATCC 700057.

Currently, neither EUCAST nor CLSI recommend the use of disc diffusion for AST of anaerobic bacteria. Disc diffusion has been investigated multiple times over the years with varying success, possible reasons being incomplete standardization of all AST ingredients and conditions. For anaerobic bacteria, everything has to be carefully standardized, including medium, inoculum, disc potency, atmosphere (and this will vary depending on the method used), temperature and time of incubation. Furthermore, anaerobic bacteria have often been studied as one entity. However, they are just as diverse a group of bacteria as all the aerobes. It is very unlikely that one set of breakpoints across a wide range of anaerobic species will perform reproducibly. A few recent attempts with disc diffusion have been made with some success using EUCAST MIC breakpoints for anaerobic bacteria. The studies have focused on a single anaerobic species or group. In a study by Erikstrup et al., it was possible to establish zone diameter breakpoints (ECOFFs) for *C. difficile* for vancomycin (5 µg) and metronidazole (5 µg) [61]. The study was performed in a standardized format using supplemented *Brucella* blood agar. However, zone diameters were compared with MICs from gradient strips and not by agar dilution. Nagy et al. investigated the *B. fragilis* group using the same standardized



**Fig. 3.** Metronidazole susceptibility testing of *Bacteroides fragilis* group isolates by the agar dilution method (the metronidazole concentration is shown below the plate). Twenty isolates were tested. One spot is free of growth lower right (negative control). From the top left to the right: the metronidazole MIC of isolates 7 and 14 can be read from the plates as 0.25 and 0.5 mg/L, respectively.

**Table 5**

Laboratory procedures for anaerobe bacteriology according to the cost effectiveness [19,21]

	Cost effective	Costly (optimal)
Transport of the specimen	In home-made anaerobe transport media, sterile specimen container	In PRAS anaerobic transport media in tube or vial
Primary plates	Home-made fresh media	Commercially available supplemented anaerobe media, PRAS media
Incubation	Anaerobic pouches, jars, boxes	Anoxomat jar system, anaerobic chamber
Identification	Presumptive identification using Gram stain, special antibiotic potency discs, spot indole, urease, catalase tests, rapid ID strips	MALDI-TOF MS, if needed 16S rRNA gene sequencing
AST	Not done, suggestion for therapy according to published surveillance data, $\beta$ -lactamase test	Gradient test, broth micro-dilution test For surveillance agar-dilution test

Abbreviations: AST, antimicrobial susceptibility testing; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PRAS, pre-reduced and anaerobically sterilized.

format of disc diffusion in comparison with agar dilution [62]. For imipenem (10  $\mu$ g), metronidazole (5  $\mu$ g) and clindamycin (10  $\mu$ g) there was very good zone diameter separation between susceptible and resistant isolates, but for piperacillin–tazobactam (30/6  $\mu$ g) this was not the case with many intermediately susceptible isolates among the susceptible. EUCAST is currently working on the development of a disc diffusion method for anaerobic bacteria, which will grow on a special rich medium with an incubation time of 24–48 h in an anaerobic environment (personal communication from EUCAST Development Laboratory, Växjö, Sweden).

The use of antioxidants (1 mg/mL ascorbic acid and 0.1 mg/mL glutathione) in the Schaedler agar medium was tested as an easy method for metronidazole MIC determination of five anaerobic culture collection strains incubated in an aerobic atmosphere for 72 h [63]. The long incubation time used and the lack of further publications comparing the data obtained with this method with those by the CLSI standard agar dilution method with anaerobic incubation, are however limitations of its applicability in routine practice.

Apart from methods that categorize isolates as S, I or R, different methods for detection of specific resistance mechanisms are also available, although the clinical implications are not always clear.  $\beta$ -lactamase disc testing including a chromogenic cephalosporin is mentioned in many guidelines, but is probably of limited value [19,56]. It is performed in the same way as with aerobic bacteria but the reaction might be slower (up to 30 min). If positive, the isolates should be considered resistant towards penicillin and ampicillin/amoxicillin. A negative test does not rule out penicillin or ampicillin/amoxicillin resistance and an MIC test should be performed. Double gradient strips with meropenem  $\pm$  EDTA can be used to detect metallo- $\beta$ -lactamase production in *B. fragilis*, although this does not always result in R categorization according to MIC breakpoints. Schwensen et al. detected metallo- $\beta$ -lactamase production in *B. fragilis* isolates with meropenem MICs as low as 0.5 mg/L, which is below the EUCAST clinical MIC breakpoint of 2 mg/L [64]. The clinical implications of low-level metallo- $\beta$ -lactamase production are not known. However, single mutations resulting in high-level resistance have been described, i.e. the presence of the *cflA* gene and/or low-level metallo- $\beta$ -lactamase production could be considered a warning [14,16]. Table 5 summarizes laboratory procedures including the specimen transportation, isolation, identification and antimicrobial susceptibility testing for different laboratories providing diagnosis of anaerobic infections according to the estimated cost.

## Conclusions

With increasing knowledge on the wide variety of anaerobic bacteria living together with humans and potentially causing serious infections, the anaerobic bacteriology in routine laboratories is becoming more and more challenging. These

microorganisms are sensitive to different oxygen levels, therefore, if we want to be sure that all possible pathogenic anaerobic bacteria will form colonies on the surface of the primary plates, we have to provide excellent culture conditions including media and anaerobic environment. The diagnostic process however, also has to differentiate infecting pathogens from those that are often just present as members of the commensal microbiota on mucosal surfaces. The clinicians' role is crucial in this process, besides considering anaerobes in many infections; they have to take samples very carefully, preventing contamination with commensal microbiota. The application of advanced DNA-based and protein-based diagnostic methods to identify known anaerobic species or to detect new genera or species, create the need for taxonomic changes. The question is how the many new names of earlier known anaerobes such as *Clostridioides* (*Clostridium*) *difficile* or *Cutibacterium* (*Propionibacterium*) *acnes* and those which were recently described as pathogens isolated from normally sterile body sites (such as *Bacteroides dorei*, *Oscillibacter ruminantium*, *Robinsoniella peoriensis*, *Ruminococcus gnavus*, *Sneathia sanguinegens*, *Solobacterium moorei*, *Turicibacter sanguinis*, etc.) will be accepted by the clinically oriented scientists.

Institutions have to allocate resources to their routine microbiology laboratories to develop expertise and practice to work with anaerobes and to be able to select the suitable laboratory procedures to give timely and useful reports to the clinicians. The laboratory staff has to determine the level of the anaerobic bacteriology they will use and also needs to carry out a risk assessment of the consequences. The financial situation will determine what kind of transport systems, media, incubation facilities and identification processes should be used to reduce potential patient harm as much as possible by neglected anaerobic infections. The ESCMID Study Group for Anaerobic Infections (ESGAI) is regularly organizing postgraduate technical workshops to provide knowledge and help for those who want to improve their service for clinicians in this field.

## Funding

No funding was received.

## Transparency declaration

The authors have no conflicts of interest to declare.

## References

- [1] Finegold SM. Anaerobic bacteria in human disease. New York: Academic Press; 1977.
- [2] Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. *Clin Microbiol Infect* 2012;12:1185–93.
- [3] Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev* 2014;38:996–1047.

[4] Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 2005;366:1079–84.

[5] Dapefrid A, Lundström B, Tano K. Prevalence of *Fusobacterium necrophorum* in tonsils from patients with chronic tonsillitis. *Acta Otolaryngol* 2017;137:297–301.

[6] Purcell RV, Pearson J, Frizelle FA, Keenan Jl. Comparison of standard, quantitative and digital PCR in the detection of enterotoxigenic *Bacteroides fragilis*. *Sci Rep* 2016;6:34554.

[7] Sears CL. Enterotoxigenic *Bacteroides fragilis*: a rogue among symbiontes. *Clin Microbiol Rev* 2009;22:349–69.

[8] Iraj B, Khorvash F, Ebneshehahidi A, Askari G. Prevention of diabetic foot ulcer. *Int J Prev Med* 2013;4:373–6.

[9] Charles PG, Uçkay I, Kressmann B, Emonet S, Lipsky BA. The role of anaerobes in diabetic foot infections. *Anaerobe* 2015;34:8–13.

[10] Nagy E, Urban E, Nord C-E. Antimicrobial susceptibility of *Bacteroides fragilis* group isolates in Europe: 20 years of experience. *Clin Microbiol Infect* 2011;17:371–9.

[11] Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. *Anaerobe* 2015;31:4–10.

[12] Veloo ACM, van Winkelhoff AJ. Antibiotic susceptibility profiles of anaerobic pathogens in The Netherlands. *Anaerobe* 2015;31:19–24.

[13] Toprak NU, Uzunguva OD, Sóki J, Soleyter G. Susceptibility profiles and resistance genes for carbapenems (*cfIA*) and metronidazole (*nim*) among *Bacteroides* species in a Turkish University Hospital. *Anaerobe* 2012;18:169–71.

[14] Hartmeyer GN, Sóki J, Nagy E, Justesen US. Multidrug-resistant *Bacteroides fragilis* group on the rise in Europe? *J Med Microbiol* 2012;61:1784–8.

[15] Sydenham TV, Sóki J, Hasman H, Wang M, Justesen US, ESGAI (ESCMID Study Group on Anaerobic Infections). Identification of antimicrobial resistance genes in multidrug-resistant clinical *Bacteroides fragilis* isolates by whole genome shotgun sequencing. *Anaerobe* 2015;31:59–64.

[16] Sóki J, Hedberg M, Patrick S, Bálint B, Herczeg R, Nagy I, et al. Emergence and evolution of an international cluster of MDR *Bacteroides fragilis* isolates. *J Antimicrob Chemother* 2016;71:2441–8.

[17] Goldstein EJC, Citron DM, Goldman P, Goldman RJ. National hospital survey of anaerobic culture and antibiotic susceptibility methods: III. *Anaerobe* 2008;14:68–72.

[18] Peeters B, Magerman K, Waumans L, Cartuyvels R. Laboratory survey and literature review of anaerobic bacteriology: foundations of a clinically orientated and evidence-based workup for anaerobic cultures. *Diagn Microbiol Infect Dis* 2016;86:15–22.

[19] Jousimies-Somer HR, Sunmanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth-KTL anaerobic bacteriology manual. Belmont, CA: Star Publishing; 2002.

[20] Hentges DJ. Anaerobes as normal flora. In: Finegold SM, George WL, editors. *Anaerobic infections in humans*. San Diego: Elsevier; 2012. p. 37–53.

[21] Clinical and Laboratory Standards Institute. Principles and procedures for detection of anaerobes in clinical specimens. Document M56-A. CLSI, Approved Guideline. Wayne, PA: CLSI; 2014.

[22] Justesen US, Skov MN, Knudsen E, Holt HM, Sogaard P, Justesen T. 16S rRNA gene sequencing in routine identification of anaerobic bacteria isolated from blood cultures. *J Clin Microbiol* 2010;48:946–8.

[23] Justesen US, Holm A, Knudsen E, Andersen LB, Jensen TG, Kemp M, et al. Species identification of clinical isolates of anaerobic bacteria: comparison of two matrix-assisted laser desorption ionization-time of flight mass spectrometry systems. *J Clin Microbiol* 2011;49:4314–8.

[24] SG1 Hansen, Skov MN, Justesen US. Two cases of *Ruminococcus gnavus* bacteremia associated with diverticulitis. *J Clin Microbiol* 2013;51:1334–6.

[25] Sydenham TV, Arpi M, Klein K, Justesen US. Four cases of bacteremia caused by *Oscillibacter ruminantium*, a newly described species. *J Clin Microbiol* 2014;52:1304–7.

[26] Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson Jr RB, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). *Clin Infect Dis* 2013;57: e22–21.

[27] Edelstein MAC. Laboratory diagnosis of anaerobic infections in humans. In: Finegold SM, George WL, editors. *Anaerobic infections in humans*. San Diego: Elsevier; 2012. p. 111–36.

[28] Brook I. Spectrum and treatment of anaerobic infections. *J Infect Chemother* 2016;22:1–13.

[29] Harrington SM. If specimen collection and processing guidelines fall, does anyone hear them? Pre-analytical conundrums in clinical microbiology. *CMN* 2014;36:105–14.

[30] Boyanova L. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. *Postgrad Med* 2017;1–6. [https://doi.org/10.1080/00325481.2018](https://doi.org/10.1080/00325481.2018.00325481).

[31] Cattoor V. *Actinobaculum schaali*: review of an emerging uropathogen. *J Infect* 2012;64:260–7.

[32] Valour F, Séchéral A, Dupieux C, Karsenty J, Lustig S, Breton P, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. *Infect Drug Resist* 2014;7:183–97.

[33] Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2016;22:S63–81.

[34] Justesen T, Justesen US. A simple and sensitive quality control method of the anaerobic atmosphere for identification and antimicrobial susceptibility testing of anaerobic bacteria. *Diagn Microbiol Infect Dis* 2013;76:138–40.

[35] Dubreuil L, Nagy E. In: Cornalgia G, Courcol R, Herrmann J-L, Khalmeter G, Peidue-Lafeuille H, Vila J, editors. *Anaerobes. European manual of clinical microbiology*. 1st ed. CFM/ESCMID; 2012. p. 197–201.

[36] Wiggs LS, Cavallaro JJ, Miller JM. Evaluation of the oxrase OxyPlate anaerobe incubation system. *J Clin Microbiol* 2000;38:499–507.

[37] Dione N, Khelaifa S, La Scola B, Lagier JC, Raoult D. A quasi-universal medium to break the aerobic/anaerobic bacterial culture dichotomy in clinical microbiology. *Clin Microbiol Infect* 2016;22:53–8.

[38] Holdeman LV, Cato EP, Moore WEC. *Anaerobe laboratory manual*. 4th ed. Blacksburg, VA: Virginia Polytechnic Institute and State University; 1977.

[39] Lee EH, Degener JE, Welling GW, Veloo AC. Evaluation of the new Vitek 2 ANC card for identification of clinical isolates of anaerobic bacteria. *J Clin Microbiol* 2011;49:1745–9.

[40] Blairon L, Maza ML, Wybo I, Piérad D, Deldite A, Vanderberg O. Vitek 2 ANC card versus BBL crystal anaerobe and RapID ANA II for identification of clinical anaerobic bacteria. *Anaerobe* 2010;16:355–61.

[41] Holland RD, Wilkes JG, Rafii F, Sutherland JB, Persons CC, Voorhees KJ, et al. Rapid identification of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* 1996;10:1227–32.

[42] Nagy E. Matrix assisted laser desorption/ionization-time-of-flight mass spectrometry: a new possibility for the identification and typing of anaerobic bacteria. *Future Microbiol* 2014;9:217–33.

[43] Garner O, Mochon A, Branda J, Burnham CA, Bythrow M, Ferraro M, et al. Multi-centre evaluation of mass spectrometric identification of anaerobic bacteria using the VITEK® MS system. *Clin Microbiol Infect* 2014;20:335–9.

[44] Veloo ACM, de Vries ED, Jean-Pierre H, Justesen US, Morris T, Urban E, et al., on behalf of the ENRI workgroup. The optimization and validation of the Biotype MALDI-TOF MS database for the identification of Gram-positive anaerobic cocci. *Clin Microbiol Infect* 2016;22:793–8.

[45] Wybo I, Soetens O, De Bel A, Echahidi F, Vancutsem E, Vandoorslaer K, et al. Species identification of clinical *Prevotella* isolates by matrix assisted laser desorption ionization time-of-flight mass spectrometry. *J Clin Microbiol* 2012;50:1415–8.

[46] Kierzkowska M, Majewska A, Kuthan RT, Sawicka-Grzelak A, Mlynarczyk G. A comparison of Api 20A vs MALDI-TOF MS for routine identification of clinically significant anaerobic bacterial strains to the species level. *J Microbiol Meth* 2013;92:209–12.

[47] Li Y, Gu B, Liu G, Xia W, Fan K, Mei Y, et al. MALDI-TOF MS versus VITEK 2 ANC card for identification of anaerobic bacteria. *J Thorac Dis* 2014;6:517–23.

[48] Nagy E, Becker S, Kostrewa M, Barta N, Urban E. The value of MALDI-TOF MS for the identification of clinically relevant anaerobic bacteria in routine laboratories. *J Med Microbiol* 2012;61:1393–400.

[49] Federko DP, Drake SL, Stock F, Murray PR. Identification of clinical isolates of anaerobic bacteria using matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Eur J Clin Microbiol Infect Dis* 2012;31:2257–62.

[50] Veloo ACM, Elgersma PE, Fridrich AW, Nagy E, von Winkelhoff AJ. The influence of incubation time, sample preparation and exposure to oxygen on the quality of the MALDI-TOF MS spectrum of anaerobic bacteria. *Clin Microbiol Infect* 2014;20:O1091–7.

[51] Hsu YMS, Burhnam CAD. MALDI-TOF MS identification of anaerobic bacteria: assessment of pre-analytical variables and specimen preparation techniques. *Diagn Microbiol Infect Dis* 2014;79:144–8.

[52] Rizzardi K, Akerlund T. High molecular weight typing with MALDI-TOF MS—a novel method for rapid typing of *Clostridium difficile*. *PLoS One* 2015;10: e0122457.

[53] Almuhayawi M, Altun O, Abdulmajeed AD, Ullberg M, Özenci V. The performance of the four anaerobic blood culture bottles Bact/ALERT-FN, -FN Plus, BACTEC-Plus and -Lytic in detection of anaerobic bacteria and identification by direct MALDI-TOF MS. *PLoS One* 2015;10(11):e0142398.

[54] Jensen A, Fago-Olsen H, Sorensen CH, Kilian M. Molecular mapping to species level of the tonsillar crypt microbiota associated with health and recurrent tonsillitis. *PLoS One* 2013;8:e56418.

[55] Claros M, Citron DM, Goldstein EJ, Merriam CV, Tyrrell KL. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections. *Diagn Microbiol Infect Dis* 2013;76:546–8.

[56] Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Document M11-A8. Approved Standard. Wayne, PA: CLSI; 2012.

[57] Heizmann W, Werner H, Herk B. Comparison of four commercial microdilution systems for susceptibility testing of anaerobic bacteria. *Eur J Clin Microbiol Infect Dis* 1988;7:758–63.

[58] Wexler HM. Susceptibility testing of anaerobic bacteria: myth, magic, or method? *Clin Microbiol Rev* 1991;4:470–84.

[59] Rennie RP, Turnbull L, Brosnoff C, Cloke J. First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution

methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species. *J Clin Microbiol* 2012;50:1153–7.

[60] EUCAST. Problems with piperacillin-tazobactam gradient tests from two manufacturers. 2015. Available at: [www.eucast.org/ast\\_of\\_bacteria/warnings/#c13111](http://www.eucast.org/ast_of_bacteria/warnings/#c13111). [Accessed 22 November 2017].

[61] Erikstrup LT, Danielsen TK, Hall V, Olsen KE, Kristensen B, Kahlmeter G, et al. Antimicrobial susceptibility testing of *Clostridium difficile* using EUCAST epidemiological cut-off values and disk diffusion correlates. *Clin Microbiol Infect* 2012;18:E266–72.

[62] Nagy E, Justesen US, Eitel Z, Urbán E, ESCMID Study Group on Anaerobic Infection. Development of EUCAST disk diffusion method for susceptibility testing of the *Bacteroides fragilis* group isolates. *Anaerobe* 2015;31:65–71.

[63] Dione N, Khelaifia S, Lagier JC, Raoult D. The aerobic activity of metronidazole against anaerobic bacteria. *Int J Antimicrob Agents* 2015;45:537–40.

[64] Schwensen SA, Acar Z, Sydenham TV, Johansson AC, Justesen US. Phenotypic detection of the *cfa*A metallo-β-lactamase in *Bacteroides fragilis* with the meropenem-EDTA double-ended Etest and the ROSCO KPC/MBL confirm kit. *J Antimicrob Chemother* 2017;72:437–40.